Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2023-06-22 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-502F1 submitted to the Ontario Securities Commission, which is a management certification related to participation fees for Class 1 and Class 3B reporting issuers. It contains detailed calculations of market values, trading periods, and fees payable, but it is primarily a certification by an officer (Corporate Secretary) confirming the accuracy and completeness of the information provided. There are no financial statements, management discussion, or detailed financial results presented. The document is regulatory in nature, focused on fee reporting and certification rather than a financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory submission and certification form rather than a full report or announcement of financial results.
2023-06-22 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is an Independent Auditor's Report for Medexus Pharmaceuticals Inc. covering consolidated financial statements for the years ended March 31, 2023 and 2022. It includes detailed audit opinions, key audit matters, and descriptions of the audit process and responsibilities. The presence of detailed financial statement components (statements of financial position, net income, changes in equity, cash flows, and notes) and the auditor's opinion on these statements indicate this is a standalone audit report. It is not the full Annual Report (10-K) because it focuses solely on the audit opinion and related audit matters without broader company activity or management discussion. The document length (15,000 characters) and content confirm it is not a brief announcement or certification. Therefore, the correct classification is Audit Report / Information (AR). FY 2023
2023-06-22 English
Code of conduct.pdf
Governance Information Classification · 95% confidence The document is titled 'Code of Business Conduct and Ethics' and contains detailed policies on ethical standards, conflicts of interest, reporting concerns, retaliation, and fair dealing. It is a governance-related document outlining internal rules and ethical guidelines for directors, officers, and employees. There is no indication that this is an annual report, financial statement, earnings release, or any other financial or regulatory filing. It is not a report publication announcement or a certification. The content aligns with governance information about company policies and board expectations. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail support this classification with high confidence.
2023-06-21 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Amendment # 2 to License & Supply Agreement' and details specific contractual amendments between two companies, including changes to pricing, forecasts, and performance requirements. It is a legal contract amendment rather than a financial report, regulatory filing, or announcement related to corporate governance, earnings, or capital structure. There is no indication of financial statements, audit information, or investor presentations. The content is focused on contractual terms and conditions between parties, which does not fit into any of the financial or regulatory report categories. Therefore, the best fitting category is 'Regulatory Filings (RNS)' as a fallback for miscellaneous filings that do not neatly fit into other categories.
2023-06-21 English
Other.pdf
Legal Proceedings Report Classification · 85% confidence The document is titled 'Amendment No 2 to License Agreement' and details specific amendments to an existing license agreement between two companies, including terms about payment and share issuance. It is a contractual amendment rather than a financial report, regulatory filing, or announcement related to corporate governance, earnings, or capital structure. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a legal agreement amendment, which is not explicitly covered by the provided categories. The closest relevant category for such contractual amendments and legal agreements is 'Legal Proceedings Report (LTR)', which includes updates on significant legal matters and agreements. Therefore, the document is best classified as a Legal Proceedings Report (LTR).
2023-06-21 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Amendment 1' and is an amendment to a License and Supply Agreement between two companies. It details the inclusion of a new trademark application into the existing agreement. The content is legal and contractual in nature, focusing on changes to an existing agreement rather than financial results, management changes, or regulatory filings. It does not contain financial data, audit information, or shareholder voting results. It is not a report or announcement related to corporate filings like annual reports, earnings, or governance. The document is best classified as a Regulatory Filing (RNS) because it is a legal amendment to a contract and does not fit into any other specific category.
2023-06-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.